An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Farxiga

Chemical Namedapagliflozin
Dosage FormTablet (oral; 5mg, 10mg)
Drug ClassInhibitors
SystemEndocrine
CompanyBristol-Myers Squibb
Approval Year2014

Indication

  • An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Last updated on 6/9/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Farxiga (dapagliflozin) Prescribing Information2014Bristol-Myers Squibb Company, Princeton, NJ
Document TitleYearSource
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation 2017NIHR
Clinical review report: dapagliflozin (forxiga).2016CADTH
Pharmacoeconomic review report: dapagliflozin (forxiga).2016CADTH
Dapagliflozin in triple therapy for treating type 2 diabetes.2016NICE
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes.2016NICE
Document TitleYearSource
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis.2020Annals of Internal Medicine
Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. 2019Diabetes Research and Clinical Practice
Document TitleYearSource
Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.2020Diabetology & Metabolic Syndrome